Roshni Pushpa Raghavan, Aiswarya Purushothaman, Ginil Kumar, Gangadharan P


Objective: Prostate cancer is the most common visceral malignancy and leading cause of cancer‑related death in men. Androgen deprivation therapy
is the established treatment of metastatic prostate cancer and has different approaches in the reduction of androgen activity including surgical
castration (bilateral orchiectomy) and medical castration (luteinizing hormone‑releasing hormone agonists/antagonists). Our purpose was to study
the clinical profile, effectiveness, and outcome of South Indian patients with metastatic prostate cancer undergoing treatment with surgical and
medical castration.
Methods: A total of 30 surgical and 30 medical castration patients diagnosed with metastatic prostate cancer between (2008 and 2009) were followed
up to 5 years. Serum prostate specific antigen (PSA) levels at the time of the first diagnosis, post‑treatment nadir PSA levels, time to nadir PSA, time
to hormonal resistance between the study groups were assessed, retrospectively. The Kaplan–Meier method was used with log‑rank test for survival
rate calculations. Gleason score, PSA levels, skeletal‑related events, and sites of metastasis of the study groups were studied.
Result: The average survival time after medical castration was 60 months and 42 months for surgical castration. No significant difference could be
established between the groups. Bone was the most common site of metastasis and radiation was the major skeletal‑related events in medical groups.
Conclusion: There were no statistical differences between the groups in terms of treatment modalities in metastatic prostate cancer.
Keywords: ???

| PDF |



Jain S, Saxena S, Kumar A. Epidemiology of prostate cancer in India.

Meta Gene 2014;2(9):596‑605.

Keating NL, O’Malley AJ, McNaughton‑Collins M, Oh WK,

Smith MR. Use of androgen deprivation therapy for metastatic prostate

cancer in older men. BJU Int 2008;101(9):1077‑83.

Carson AP, Howard DL, Carpenter WR, Taylor YJ, Peacock S,

Schenck AP, et al. Trends and racial differences in the use of androgen

deprivation therapy for metastatic prostate cancer. J Pain Symptom

Manage 2010;39(5):872‑81.

Connolly RM, Carducci MA, Antonarakis ES. Use of androgen

deprivation therapy in prostate cancer: Indications and prevalence.

Asian J Androl 2012;14(2):177‑86.

Gandaglia G, Karakiewicz P, Sun M. Beyond the bone: Atypical

metastases in prostate cancer. Cancer Cell Microenviron


Auclerc G, Antoine EC, Ajfinger FC, Cajfinger F, Brunet‑Pommeyrol A,

Khayat D, et al. Management of advanced prostate cancer. Oncologist


Bayraktar S, Wahab MA. Current medical and surgical options for

androgen deprivation in prostate cancer patients. Open Prostate Cancer

J 2010;2(3):55‑8.

Abouelfadel Z, Crawford ED. Leuprorelin depot injection: Patient

considerations in the management of prostatic cancer. Ther Clin Risk

Manag 2008;4(2):513‑26.

Akinremi TO, Ogo CN, Olutunde AO. Review of prostate cancer

research in Nigeria. Infect Agent Cancer 2011;6(2):10‑8.

Hotte SJ, Saad F. Current management of castrate‑resistant prostate

cancer. Curr Oncol 2010;17 Suppl 2:S72‑9.

Clarke JM, Armstrong AJ. Novel therapies for the treatment of advanced

prostate cancer. Curr Treat Options Oncol 2013;14(1):109‑26.

Pourmand G, Salem S, Mehrsai A, Lotfi M, Amirzargar MA, Mazdak H,

et al. The risk factors of prostate cancer: A multicentric case‑control

study in Iran. Asian Pac J Cancer Prev 2007;8(3):422‑8.

Leitzmann MF, Rohrmann S. Risk factors for the onset of prostatic

cancer: Age, location, and behavioral correlates. Clin Epidemiol


Singh S, Raguvaran R, Rajkumar K. Factors influencing prostate

cancer. Int J Pharm Sci 2014;6:33‑5.

Kolonel LN. Fat, meat, and prostate cancer. Epidemiol Rev


Ganesh B, Saoba SL, Sarade MN, Pinjari SV. Risk factors for prostate

cancer: An hospital‑based case‑control study from Mumbai, India.

Indian J Urol 2011;27(3):345‑50.

Martel CL, Gumerlock PH, Meyers FJ, Lara PN. Current strategies in

Purushothaman et al.

the management of hormone refractory prostate cancer. Cancer Treat

Rev 2003;29(3):171‑87.

Gandaglia G, Karakiewicz PI. Maxine sun beyond the bone:

Atypical metastases in prostate cancer. Cancer Cell Microenviron


Winer AG, Sfakianos JP, Hyacinthe LM, McNeil BK. A 10‑year

analysis of metastatic prostate cancer as an initial presentation in an

underserved population. Int Braz J Urol 2014;40(3):30‑41.

Demir A, Cecen K, Karadag MA, Kocaaslan R, Turkeri L. The course

of metastatic prostate cancer under treatment. Springerplus 2014;3:725.

Asian J Pharm Clin Res, Vol 9, Issue 2, 2016, 51-54

Botto H, Rouprêt M, Mathieu F, Richard F. Multicentre randomized

trial comparing triptorelin medical castration versus surgical castration

in the treatment of locally advanced or metastatic prostate cancer. Prog

Urol 2007;17(2):235‑49.

Yang C, Qi GS, Rong RM, He J. Clinical features and treatment

strategies for older prostate cancer patients with bone metastasis. Asian

J Androl 2013;15(6):759‑63.

Broder MS, Gutierrez B, Cherepanov D, Linhares Y. Burden of

skeletal‑related events in prostate cancer: Unmet need in pain

improvement. Support Care Cancer 2015;23:237‑47.

About this article





Additional Links

Manuscript Submission


Asian Journal of Pharmaceutical and Clinical Research
Vol 9 Issue 2 (March-April) 2016 Page: 51-54

Print ISSN


Online ISSN


Authors & Affiliations

Roshni Pushpa Raghavan

Aiswarya Purushothaman

Ginil Kumar

Gangadharan P

Article Tools

Email this article (Login required)
Email the author (Login required)


  • There are currently no refbacks.